PDS Biotechnology Corporation - חוב לטווח קצר של החברה PDSB

PDS Biotechnology depends on funding and the outcome of Versamune tests. Short-term borrowings under one year on the GURU.Markets base chart contain data where 0.00 is the current value of the indicator. Growth potential is based on T-cell therapy for cancer patients, while business protection relies on patent developments that have not yet generated commercial profit.

With negative cash flow, PDS Biotechnology is critically dependent on external financing, making the monitoring of short-term debt with maturities of up to one year a key tool for assessing liquidity. This indicator captures obligations with a repayment horizon of up to twelve months, allowing for a comparison between the growth rate of the credit load and the absence of commercial revenue to determine the sustainability of the innovative business.